Abstract: 2-substituted glutamic acid derivative according to the formula (I) or its physiologically acceptable salts are useful to impart, enhance or modify umami-and/or salt taste in a comestible product.

Abstract: Microspheres are produced by contacting a solution of a macromolecule or small molecule in a solvent with an antisolvent and a counterion, and chilling the solution. The microspheres are useful for preparing pharmaceuticals, nutraceuticals, cosmetic products and the like of defined dimensions.

Abstract: Salts of kukoamine B, their preparation method and their pharmaceutical use in preparation of drugs for preventing and treating sepsis. Experiments indicate that salts of kukoamine B have a good effect on antagonizing the key factors inducing sepsis, and can be used in the preparation of drugs for preventing and treating sepsis. Under the current circumstances of the lack of effective measures for the treatment of sepsis in clinical practice, the medicinal formulations, which comprise the salts of kukoamine B, pharmaceutically acceptable carrier and/or diluent, provide a new approach for the prevention and treatment of sepsis.

Abstract: The present invention provides a method for separating an amide from an amino acid ionic liquid. The method includes the step of providing a polar solvent and an extracting agent to the amino acid ionic liquid, so as to separate the amide from the amino acid ionic liquid. In the method of the present invention, there is no need to add ammonium for neutralization, such that no byproduct, ammonium sulfate, is formed. In addition, after the amide is separated from the amino acid ionic liquid, the amino acid ionic liquid can be recycled.

Abstract: The present invention relates to novel particles comprising polyelectrolyte polymers which are transporters of active principle (AP), in particular protein and peptide active principle, and to novel modified-release pharmaceutical formulations comprising said AP microparticles. These novel particles loaded with AP release the AP over a prolonged period of time of several days, or even several weeks.

Abstract: The present invention provides an improved method for preparing, purifying, precipitating, etc., a subject compound for use in a subsequent reaction carried out in suspension. The present invention relies on a precipitating solvent being added to an aqueous solution comprising the subject compound to form a precipitate of the subject compound, which may be further dried and/or purified. Compositions made according to present methods have improved characteristics and properties, such as increased surface and/or reduced density, resulting in a higher reactivity in a subsequent reaction carried out in suspension.

Abstract: Disclosed herein is a method for producing a flavoring containing L-glutamic acid derived from natural foods by adjusting the content of ammonia remaining in a final fermentation broth after completion of culture to be in the range of 0 to 10 g/L in cultivation of L-glutamic acid producing microorganisms, thereby facilitating drying of the fermentation liquor containing L-glutamic acid. A flavoring produced by the method is also disclosed.

Abstract: The present invention encompasses a method for screening for a kokumi-imparting substance by using the calcium receptor activity as an index, a composition containing a kokumi-imparting substance obtained by the screening method, a method for producing food or drink imparted with kokumi, and food or drink imparted with kokumi.

Abstract: The present invention provides a catalyst composition for preparing an amide, including an amino acid ionic liquid having a cation of formula (I) and an anion selected from the group consisting of an inorganic acid group, an organic acid group and a combination thereof, wherein the numbers of the anion and the cation are such that the amino acid ionic liquid is electroneutral; and a Bronsted acid. The present invention also provides a method for preparing an amide in the presence of the catalyst composition, and the method has advantages such as decreasing viscosity of ionic liquid, and increasing conversion rate of ketoximes and selectivity of amides.

Abstract: A monitoring test for recurrent breast cancer with a high degree of sensitivity and specificity is provided that detects the presence of a panel of multiplicity of biomarkers that were identified using metabolite profiling methods. The test is capable of detecting breast cancer recurrence about a years earlier than current available monitoring diagnostic tests. The panel of biomarkers is identified using a combination of nuclear magnetic resonance (NMR) and two dimensional gas chromatography-mass spectrometry (GC×GC-MS) to produce the metabolite profiles of serum samples. The NMR and GC×GC-MS data are analyzed by multivariate statistical methods to compare identified metabolite signals between samples from patients with recurrence of breast cancer and those from patients having no evidence of disease.

Abstract: This invention relates to octahydro-binaphthol derivatives, which can recognize amino acids and amino alcohols enantioselectively and transform L-amino acids into D-amino acids and optically resolve amino acids or amino alcohol with high efficiency.

Abstract: Disclosed is an agent for use in the treatment or prevention of inflammatory bowel disease. Also disclosed is an agent for inhibiting the production of TNF-?. A therapeutic or prophylactic agent for inflammatory bowel disease comprising at least one amino acid selected from the group consisting of lysine, histidine, phenylalanine, methionine, tryptophan, glutamine, glycine, cysteine, cystine and threonine, the amino acid being administered at a dose of 0.1 to 4000 mg/kg per day; and a TNF-? production inhibitor comprising an amino acid selected from the group consisting of histidine, phenylalanine and tryptophan, the amino acid being administered at a dose of 0.1 to 4000 mg/kg per day.

Abstract: Process to prepare coated particles containing a particle and a coating, wherein the particle contains glutamic acid N,N-diacetic acid or a (partial) salt thereof of the formula HnYm-GLDA, wherein Y is a cation selected from the group of sodium, potassium, lithium, and mixtures thereof, n+m=4, in which the particle is made from a solution containing glutamic acid N,N-diacetic acid or a partial salt thereof that has a p H of between 4 and 11, and subsequently or simultaneously the coating is applied on the particle, to an intermediate particle of HnYm-GLDA, wherein n is 0.1-3.2 and m is 0.8-3.9, the coated particle obtainable with the process, and the use thereof.

Abstract: To provide a nucleic-acid-transfecting composition which exhibits low cytotoxicity, which facilitates a nucleic acid transfection into cells, and which improves expression of the nucleic acid in the cells. The invention provides a composition for transfecting a nucleic acid into a cell, including a compound represented by the following formula (I) (wherein each of R1 and R2, which are identical to or different from each other, represents a saturated or unsaturated hydrocarbon group; R3 represents a C1-6 alkyl group or a C1-6 hydroxyalkyl group; m is an integer from 1 to 10; and X represents a halogen atom), and a phospholipid.

Abstract: This present invention provides crystallization of ?-form crystals preferentially which are metastable crystals without precipitating ?-form crystals. This method allows for the precipitation of ?-form crystals which are metastable crystals by combining (a) the process of achieving supersaturation by mixing an acidic solution with an aqueous solution containing glutamic acid to attain a pH at the isoelectric point of glutamic acid or lower, and (b) after a certain elapsed time, adding more of the aqueous glutamic acid solution to achieve a second supersaturation.

Abstract: Disclosed are: a composition for alleviating ultraviolet irradiation-induced damage, which can be used on a daily based and is stable and safe; and a pharmaceutical preparation, a cosmetic and a food composition, each of which comprises the composition. The composition for alleviating ultraviolet irradiation-induced damage contains one or more compounds selected from the group consisting of D-glutamic acid, L-glutamic acid, D-proline, D-cystine, L-cystine, and derivatives and/or salts of the aforementioned compounds. The composition can be used as an external formulation for the skin, a cosmetic composition, an anti-wrinkle agent, a sunscreen agent, a pharmaceutical composition for treating and/or preventing skin diseases, a food composition, or a pharmaceutical composition for preventing or treating cataract.

Abstract: Microspheres are produced by contacting a solution of a macromolecule or small molecule in a solvent with an antisolvent and a counterion, and chilling the solution. The microspheres are useful for preparing pharmaceuticals, nutraceuticals, cosmetic products and the like of defined dimensions.

Abstract: A new method for preparing salts of metal cations and organic acids, especially divalent salts of alkaline earth metal ions from group II of the periodic system and carboxylic acids. The method comprising the use of a high temperature (about 90° or more) and, optionally. high pressure, in order to obtain a higher yield, purity and faster reaction speed than obtained with known synthesis methods. In particular, the present invention relates to the production of strontium salts of carboxylic acids. Novel strontium salts are also provided by the present method.

Abstract: A method for producing a fermentation product from a lignocellulose-containing material comprises pre-treating the lignocellulose-containing material; introducing a cationic polysaccharide to the pre-treated lignocellulose-containing material; exposing the pre-treated lignocellulose-containing material to an effective amount of a first hydrolyzing enzyme; and fermenting with a fermenting organism to produce a fermentation product. The cationic polysaccharide may be a cationic starch.

Abstract: A composition which enhances the saltiness and the salty flavor of food or drink, and a method for enhancing the saltiness and the salty flavor of food or drink are described. The composition contains magnesium glutamate, and can be used to improve a decrease in the taking ratio of a food or a drink, which contains sodium chloride in a reduced amount, because of the lack of the salty taste thereof.

Abstract: The present invention relates to stroke-targeting peptides and use thereof. More specifically, the present invention relates to a stroke-targeting peptide comprising an amino acid sequence selected from the group consisting of SEQ ID NO: 1 to SEQ ID NO: 4 and use thereof. The peptide of the present invention can be specifically bound to stroke cells in the subject, and thus can be effectively used in diagnostic markers and kits for stroke, and compositions for drug delivery specific to stroke and pharmaceutical compositions and compositions for imaging stroke.

Abstract: The present invention encompasses a method for screening for a kokumi-imparting substance by using the calcium receptor activity as an index, a composition containing a kokumi-imparting substance obtained by the screening method, a method for producing food or drink imparted with kokumi, and food or drink imparted with kokumi.

Abstract: This present invention provides crystallization of ?-form crystals preferentially which are metastable crystals without precipitating ?-form crystals. This method allows for the precipitation of ?-form crystals which are metastable crystals by combining (a) the process of achieving supersaturation by mixing an acidic solution with an aqueous solution containing glutamic acid to attain a pH at the isoelectric point of glutamic acid or lower, and (b) after a certain elapsed time, adding more of the aqueous glutamic acid solution to achieve a second supersaturation.

Abstract: The invention relates to novel materials based on biodegradable polyamino acids that are useful for vectorizing active principle(s)(AP). The aim of the invention is to supply a new polymeric raw material that is used for vectorizing AP and optimally fulfills all requirements concerning biocompatibility, biodegradability, the ability to be easily associated with numerous active principles or solubilize the active principles and to release the active principles in vivo. Such polymers can also be readily and economically transformed into particles vectorizing active principles according to the grafting rate of the hydrophobic groups, said particles being able to form stable aqueous colloidal suspensions.

Abstract: The invention relates to novel materials based on biodegradable homopolyamino acids and which can be used for the vectorization of (an) active ingredient(s) (AI). The invention also relates to novel pharmaceutical, cosmetic, dietetic or phytosanitaty compositions based on homopolyamino acids. The invention can produce a novel polymer raw material which can be used for the vectoiization of Al that can optimally be: biocompatible, biodegradable, capable of becoming easily associated with a large number of active ingredients or solubilizing them and releasing the active ingredients in vivo. According to the present invention, which primarily relates to linear homopolyamino acids having aspartic or glutamic units and whose attachments can include hydrophobic groups having 8-30 carbon atoms. The homopolymers are amphiphilic and anionic and can easily be transformed at low cost into particles for the vectorization of active ingredients. The particles can form stable aqueous colloidal suspensions.

Abstract: A new method for preparing salts of metal cations and organic acids, especially divalent salts of alkaline earth metal ions from group II of the periodic system and carboxylic acids. The method comprising the use of a high temperature (about 90° or more) and, optionally. high pressure, in order to obtain a higher yield, purity and faster reaction speed than obtained with known synthesis methods. In particular, the present invention relates to the production of strontium salts of carboxylic acids. Novel strontium salts are also provided by the present method.

Abstract: The present invention relates to liposomes and virosomes and, more particularly, to liposomal and virosomal delivery systems for transporting materials such as drugs, nucleic acids and proteins.

Abstract: The present invention relates to the use of an inhibitor of CTP synthetase, such as a glutamine analogue, and a substance capable of suppressing toxic effects thereof in vivo, in the manufacture of a medicament for the treatment of a disease caused by a parasitic protozoa. More specifically, said substance capable of suppressing toxic effects may be a nucleobase, such as a purine base or a nucleoside, while the glutamine analogue advantageously is 6-diazo-5-oxo-L-norleucine (DON). The invention also relates to a pharmaceutical composition as such for the treatment and/or prevention of a disease caused by a parasitic protozoa, wherein the disease is selected from the group consisting of malaria, leishmaniasis and trypanosomiasis, e.g. American trypanosomiasis (Chaga's disease), or African trypanosomiasis (African sleeping sickness).

Abstract: Neutral alpha amino diacid complexes of trace minerals and their use for animal nutrition.

Abstract: Disclosed are pyroglutamic acid derivatives and related compounds which bind VLA-4. Certain of these compounds also inhibit leukocyte adhesion and, in particular, leukocyte adhesion mediated by VLA-4. Such compounds are useful in the treatment of inflammatory diseases in a mammalian patient, e.g., human, such as asthma, Alzheimer's disease, atherosclerosis, AIDS dementia, diabetes, inflammatory bowel disease, rheumatoid arthritis, tissue transplantation, tumor metastasis and myocardial ischemia. The compounds can also be administered for the treatment of inflammatory brain diseases such as multiple sclerosis.

Abstract: Compounds of the formula I, in which R1, R2, R3, R4, R5, and R6 have the meanings given in the description, and their physiologically acceptable salts. The compounds are suitable for use, for example, as hypolipidemics.

Abstract: A process for synthesizing substantially enantiomerically pure L-amino acids, particularly L-?-methylene glutamic acid, and esters and salts thereof. The process includes the derivatization of (2S)-pyroglutamic acid, and the decyclization of the resulting derivative to form the desired end product.

Abstract: Disclosed are methods of inhibiting neovascularization in a subject by administering to the subject a pharmaceutical preparation of R?-Glu-Trp-R?.

Abstract: Disclosed herein is a method of purifying L-glutamic acid by transformation recrystallization which method comprises maintaining crude crystals of L-glutamic acid containing ? crystals of L-glutamic acid in an aqueous solvent at a temperature of from 50° C. to the boiling point of said aqueous solvent in the coexistence of active carbon until about 30% or more of the crystals of L-glutamic acid have been transformed into ? crystals thereof, the amount of said aqueous solvent being an amount not more than the amount sufficient (i.e., an amount insufficient) to form a saturated solution of said crystals of L-glutamic acid, according to which method purified crystals of L-glutamic acid can be obtained extremely rapidly and in high yields, and remarkably conveniently and easily on an industrial scale, as compared with the conventional transformation recrystallization method which is a hitherto common purification method of L-glutamic acid.

Abstract: A composition for livestock feed, comprising a feed for livestock and at least two additives selected from the group consisting of nucleic acid, glutamine and glutamic acid; and a method for increasing body weight gain efficiency and feed efficiency in livestock, comprising administering the above composition for livestock feed to livestock.

Abstract: Disclosed herein is a method of purifying L-glutamic acid by transformation recrystallization which method comprises maintaining crude crystals of L-glutamic acid containing a crystals of L-glutamic acid in an aqueous solvent at a temperature of from 50° C. to the boiling point of said aqueous solvent in the coexistence of active carbon until about 30% or more of the crystals of L-glutamic acid have been transformed into &bgr; crystals thereof, the amount of said aqueous solvent being an amount not more than the amount sufficient (i.e., an amount insufficient) to form a saturated solution of said crystals of L-glutamic acid, according to which method purified crystals of L-glutamic acid can be obtained extremely rapidly and in high yields, and remarkably conveniently and easily on an industrial scale, as compared with the conventional transformation recrystallization method which is a hitherto common purification method of L-glutamic acid.

Abstract: The present invention provides a method for enantioselectively reducing a prochiral carbon centered radical having one or more electron donator groups attached directly to the central prochiral carbon atom of the radical, and/or attached to a carbon atom within 1 to 4 atoms of the central prochiral carbon atom, comprising treating said radical with a chiral non-racemic organotin hydride in the presence of a Lewis acid.

Abstract: The present invention relates to a process for the resolution of DL-racemic mixtures of compounds which crystalize in the form of a conglumerate. Both, the D and L-enantiomers are obtained according to the invention in a industrially feasable process by adding chiral enantioselective polymers to the supersaturated solution of the racemat to inhibit crystalization of one enantiomer. Next a DL-racemic mixture of said compound is suspended in about twice the amount of the crystallized enantiomer. Consequently, the opposite enantiomer could be recovered by said suspension by physical separation.

Abstract: The present invention provides a glutathione derivative having a dramatically enhanced hematopoiesis promoting effect in the living body represented by the formula (I): where A represents H or a C1-C20 acyl group; R1 represents a C1-C26 alkyl group or a C3-C26 alkenyl group; and R2 represents H, a C1-C26 alkyl group or a C3-C26 alkyl group, with the proviso that compounds are excluded in which R1 is a C1-C10 alkyl group or a C3-C10 alkenyl group, and simultaneously R2 is H, a C1-C10 alkyl group or a C3-C10 alkenyl group. The present invention also provides a salt of the glutathione derivative, or a colloidal composition that enables the safe and effective development of the effects of the glutathione derivative in the living body.

Abstract: Compounds of Formula I, and pharmaceutical compositions containing these compounds, activate the insulin receptor kinase, which leads to an increased sensitivity to insulin and an increase in glucose uptake, and are therefore useful for the treatment of animals, especially humans, with hyperglycemia, especially for the treatment of type 2 diabetes. Processes for preparation of the compounds, and their use in assays, are also disclosed.

Abstract: One aspect of the present invention relates to 2-hydroxymethylglutamic acid and congeners thereof. A second aspect of the invention relates to a method of synthesizing 2-hydroxymethylglutamic acid and congeners thereof.

Abstract: Monohydroxamate vanadium complexes of the formula (1): R—CO—NHOH.X, wherein R is a residue selected from: (i) H2N—CH(COY)—(CH2)n—, wherein n is 1, 2 or 3, and Y is OH or NH2; (ii) H2N—CH2—S—CH2—; and (iii) pyridyl, piperidyl or tetrahydroisoquinolinyl; and X is a vanadium compound selected from a vanadyl (VO2+), metavanadate (VO3−)or vanadate (VO43−)) salt, are useful for inducing normoglycemia and/or reducing blood glucose levels in diabetic patients.

Abstract: A method for recovering amino acids, which comprises supplying a mixed solution containing inorganic acid salts, amino acids and non-electrolytes such as saccharides to a first-step resin layer comprising an Na type or K type strongly acidic ion exchange resin; separating an effluent into at least a first fraction containing coloring matters, acidic amino acids and ashes, a second fraction containing neutral amino acids and saccharides, and a third fraction containing betaines; supplying the second fraction to a second-step resin layer comprising at least one resin selected from the group consisting of NH4 type, Ca type and Mg type strongly acidic ion exchange resins, and optionally further supplying it to a third-step resin layer comprising an Mg type or Ca type strongly acidic ion exchange resin different from the resin of the second-step resin layer, thereby recovering various kinds of amino acids contained in an effluent.

Abstract: The present invention relates to novel compounds that are useful for inhibition and prevention of cell adhesion and cell adhesion-mediated pathologies. This invention also relates to pharmaceutical formulations comprising these compounds and methods of using them for inhibition and prevention of cell adhesion and cell adhesion-mediated pathologies. The compounds and pharmaceutical compositions of this invention can be used as therapeutic or prophylactic agents. They are particularly well-suited for treatment of many inflammatory and autoimmune diseases.

Abstract: Compounds selected from those of general formula and A is selected from specified aminoacyl compounds are inhibitors of DP-IV mediated processes.

Abstract: An indirect acidulation process for producing glutamic acid from an aqueous feed containing a glutamate resulting from fermentation includes: a) contacting an aqueous feed stream at an elevated temperature with a weak acid cation exchanger (WACE) which is at least partially in its acid form, whereby a part of the cations in the solution is taken up by the cation exchanger and protons are introduced into the solution; b) contacting a second aqueous feed containing glutamate and cations at an elevated temperature with a strong acid cation exchanger (SACE) that is obtained from a subsequent step and carries cationic glutamate, whereby the cationic glutamate is transferred into the solution and most of the cations in the second aqueous feed are taken up by the SACE; c) crystallizing glutamic acid from the effluent of step (b); d) contacting the mother liquor of step (c) with the SACE which is at least partially in its acid form whereby cationic glutamate is bound; e) utilizing the SACE obtained in step (d) in ste

Abstract: A process for the optical resolution of racemic 3-(p-chlorophenyl)glutaramide (GAM) into its R isomer R--COOH and its S isomer S--COOH, which process includes the steps of either:(1) reacting racemic 3-(p-chlorophenyl)-glutaramide dissolved in a suitable solvent with S-(-)-.alpha.-methylbenzylamine of the formula H.sub.2 N--S'(2) precipitating out of the solution of step (1) R--CO.sub.2.sup.-.H.sub.3.sup.+ N--S';(3) dissolving the precipitate of step (2) in water, with the addition of a suitable acid; and(4) precipitating out of the solution of step (3) R--COOH; or(5) reacting racemic -3-(p-chlorophenyl)-glutaramide dissolved in a suitable solvent with R-(+)-.alpha.-methylbenzylamine of the formula H.sub.2 N--R';(6) precipitating out of the solution of step (5) S--CO.sub.2.sup.-.H.sub.3.sup.+ N--R';(7) dissolving the precipitate of step (6) in water, with the addition of a suitable acid, and(8) precipitating out of the solution of step (7) S--COOH.

Abstract: A chromogenic receptor comprises a self-assembled chromogenic compound having at least one intrinsic binding site. The chromogenic compound is characterized by the property of producing a reversible color change responsive to binding a target substrate to the receptor. The chromogenic compound has a transition metal ion and at least one ligand bound to the transition metal ion. The ligand is selected from the group consisting of substituted phenanthroline, substituted 2,2'-bipyridine and substituted 2,2':6',2"-terpyridine. The transition metal is selected from the group consisting of Cu(I), Cu(II), Ag(I), Ni(II), Fe(II), Fe(III), Ru(II), Co(III), and Os(II). Self-assembly can be effected in the presence of Cu(I) to form receptors for dicarboxylic acids, carbohydrate, amino acids, steroids and pyrophosphates. The receptors are characterized by the formation of a 2:1 complex of the target substrate with the receptor producing a visible color change from orange to red and a measurable change in its luminescence.

Abstract: Described herein is a novel process to resolve a racemic compound into its optically active isomers without need for chemical transformation such as salt formation. The process advantageously utilizes polymers containing chiral moieties in their repeat units as well as exhibiting critical solution temperature behavior in a suitable solvent. An embodiment describes the resolution of tryptophan.

Abstract: A pharmaceutical compound of the formula: ##STR1## in which n is 1 or 2, R.sup.1 is --CO.sub.2 H, R.sup.2 is hydrogen or C.sub.1-4 alkyl andR.sup.3 is hydrogen, C.sub.1-10 alkyl, C.sub.2-10 alkenyl, optionally substituted phenyl, optionally substituted phenyl-C.sub.1-4 alkyl, optionally substituted phenyl C.sub.2-10 alkenyl,(optionally substituted phenyl).sub.2 -C.sub.1-4 alkyl, optionally substituted C.sub.3-7 cycloalkyl, optionally substituted C.sub.3-7 cycloalkyl-C.sub.1-4 alkyl or optionally substituted C.sub.3-7 cycloalkyl-C.sub.2-10 alkenyl, orR.sup.2 and R.sup.3, together with the carbon atom to which they are attached, form an optionally substituted C.sub.4-7 cycloalkyl group;or a salt or ester thereof other than the compounds .gamma.-propylidene-L-glutamic acid, .gamma.-ethylidene-L-glutamic acid and .gamma.-methylidene-L-glutamic acid.